The Europe Large And Small-scale Bioprocessing Market would witness market growth of 13.8% CAGR during the forecast period (2023-2030).
The biopharmaceutical industry primarily drives the market, which includes the production of monoclonal antibodies, vaccines, recombinant proteins, and other biologics. The demand for these products continues to grow because of their effectiveness in treating various diseases. The adoption of single-use bioprocessing technologies has accelerated, offering cost-effective and flexible solutions for large-scale production. This trend has streamlined production processes and reduced the need for extensive cleaning and sterilization of equipment.
The market has seen remarkable growth, driven by the development and commercialization of cell and gene therapies. These therapies hold promise for treating a wide range of diseases and have attracted substantial investment and research. The trend toward personalized medicine, which requires the ability to process smaller batches tailored to individual patients, is boosting the market. Integrating microfluidic technologies into small-scale bioprocessing has facilitated the development of miniaturized devices for cell culture, assays, and drug discovery.
The U.K. has a thriving biotechnology startup ecosystem, and these startups often rely on small-scale bioprocessing for their research and development efforts. Their work spans various therapeutic areas, including oncology, rare diseases, and personalized medicine. The application of biopharmaceuticals in the U.K. has a dual impact on the market. Large-scale facilities cater to the commercial production and export of biopharmaceuticals, while small-scale laboratories foster innovation, research, and development, making the U.K. a hub for bioprocessing activities and biopharmaceutical advancements. The factors mentioned above will drive the regional market growth.
The Germany market dominated the Europe Large And Small-scale Bioprocessing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $10,102.6 million by 2030. The UK market is showcasing a CAGR of 12.8% during (2023 - 2030). Additionally, The France market would register a CAGR of 14.6% during (2023 - 2030).
Based on Scale, the market is segmented into Industrial Scale, and Small Scale. Based on Use Type, the market is segmented into Multi Use, and Single Use. Based on Mode, the market is segmented into In-house, and Outsourced. Based on Application, the market is segmented into Biopharmaceuticals, Speciality Industrial Chemicals, and Environmental Aids. Based on Workflow, the market is segmented into Industrial Downstream Processing, Fermentation, and Upstream Processing. Based on Product, the market is segmented into Bioreactors/Fermenters, Cell Culture Products, Filtration Assemblies, Bioreactors Accessories, Bags & Containers, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Large And Small-scale Bioprocessing Market will Hit $159.6 Billion by 2030, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., GE healthcare, Corning Incorporated, Sartorius AG, Lonza Group AG (Capsugel), Meissner Filtration Products, Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd. and Eppendorf SE.
By Scale
By Use Type
By Mode
By Application
By Workflow
By Product
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
